Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Point Biopharma Global's stock jumps more than 80% after Lilly merger deal
06:56am, Tuesday, 03'rd Oct 2023
Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based cancer
Drugmakers sign on to negotiate Medicare prices under protest
01:02pm, Monday, 02'nd Oct 2023
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
11:32am, Monday, 02'nd Oct 2023
With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500.
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
11:28am, Monday, 02'nd Oct 2023
Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.
Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs.
08:05am, Monday, 02'nd Oct 2023
The pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facility
06:59am, Monday, 02'nd Oct 2023
Eli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for moderate-to-severe atopic dermatitis, after an inspection
U.S. FDA declines to approve Eli Lilly's skin disease drug
06:54am, Monday, 02'nd Oct 2023
The U.S. Food and Drug Administration has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings during an inspection of a contract manufacturer, the company said
Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer
05:43pm, Friday, 29'th Sep 2023
Chris Shibutani, Goldman Sachs Senior Analyst, joins 'Closing Bell Overtime' to talk his top picks in the biotech sectors.
3 Stocks to Focus on as Demand for Obesity Drugs Booms
11:17am, Friday, 29'th Sep 2023
The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's N
Eli Lilly settles whistleblower lawsuit over manufacturing problems
05:18pm, Thursday, 28'th Sep 2023
Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
08:45am, Thursday, 28'th Sep 2023
The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
04:34pm, Tuesday, 26'th Sep 2023
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three pa
Don't Miss the Boom: 3 Biotech Stocks Set to Explode Higher
01:00pm, Tuesday, 26'th Sep 2023
In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast resear
2 Magnificent Dividend Stocks to Buy Right Now
01:00pm, Tuesday, 26'th Sep 2023
High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospe
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease
01:32pm, Monday, 25'th Sep 2023
Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.
